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SUMMARY – Splenic irradiation has long been known as a palliative treatment modality in 
patients with various malignant hematologic diseases aiming to ameliorate clinical symptoms of 
splenomegaly as well as clinical sequels of hypersplenism. It provides considerable effect with low 
toxicity although exact radiotherapy dose and fractionation schedule are not known.  During the 
1996-2010 period, eleven patients were treated at our institution with splenic irradiation. They rece-
ived 16 courses of fractionated radiotherapy. There were six patients with non-Hodgkin’s lymphoma, 
four with chronic lymphocytic leukemia, and one patient with myelofibrosis. The median of the dose 
received was 7 Gy, while the median of dose received per fraction was 1 Gy. Both parallel opposed 
anterior-posterior fields and tangential fields were used. Due to the clinical target volume shrinkage, 
the treatment field was reduced in 44% of courses. Of the courses initiated for symptom control, 71% 
resulted in effective palliation, whereas of the courses started to treat hematologic sequels of hyper-
splenism 50% produced desirable effects. The most common side effects included thrombocytopenia 
and anemia. Splenic irradiation provides effective and low-toxic palliation of symptoms but it is 
much less successful in treating hematologic disorders caused by hypersplenism. 
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Introduction 
Splenic irradiation is the oldest known treatment 
for various neoplastic hematologic diseases. It was first 
applied in leukemias one century ago and remained the 
only effective treatment for years1. The advent of po-
tent anti-neoplastic drugs restricted the use of splenic 
irradiation merely to palliative treatment of splenom-
egaly, treatment of rare lymphoproliferative diseases 
like prolymphocytic leukemia, hairy cell leukemia or 
some cases of mantle zone non-Hodgkin’s lymphoma 
(NHL), and treatment of refractory chronic lympho-
cytic leukemia (CLL).
Splenomegaly is the leading clinical sign in various 
lymphoid and myeloid malignancies. Splenic irradia-
tion is effective in palliation of symptoms associated 
with splenomegaly such as abdominal tumor, pain, 
anemia, and thrombocytopenia2. Favorable effects 
of splenic irradiation are mainly connected with two 
mechanisms: reduction of spleen tumor burden (de-
creasing splenomegaly) and suppression of splenic re-
ticuloendothelial system. There are a number of stud-
ies showing therapeutic effect of splenic irradiation 
in a variety of hematologic malignancies3-7. The main 
reason for using splenic irradiation is the fact that it is 
a low-toxic and easily applicable palliative treatment. 
Lymphoid tumor tissue is sensitive to therapeutic ra-
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diation and very low doses of 0.05-0.5 Gy are capable 
of inducing apoptosis in thymic or splenic tissue8. So, 
for splenic irradiation, low total doses and small frac-
tions of fractionated radiotherapy have been success-
fully used. 
In this paper, we present 11 patients that received 
splenic irradiation (six patients with NHL, four pa-
tients with CLL and one patient with myelofibrosis). 
The indications, setting, results and toxicity profile are 
discussed.  
Patients and methods
During the 1996-2010 period, 11 patients were 
treated with splenic irradiation at our institution and 
their case records were reviewed. All patients had 
splenomegaly with secondary hypersplenism, and 
were referred for palliative splenic irradiation at our 
department. Hematologists were responsible for cyto-
toxic treatment and follow up of these patients. When 
splenic irradiation was considered as the treatment of 
choice, patients were presented to radiation oncologist 
for further radiation treatment. 
Radiotherapy was delivered with cobalt unit. De-
pending on spleen size, a direct field or two opposite 
fields were used to cover palpable splenomegaly in 
most patients. During the treatment, each patient was 
closely monitored before each fraction of radiotherapy 
with complete blood count and clinical examination 
to assess changes in the spleen size. Both were used 
to assess toxicity. In some cases, even ultrasonogra-
phy was used to modify target volume. The treatment 
was administered until achieving the desired splenic 
shrinkage, withdrawal of symptoms, or the occur-
rence of unacceptable toxicity. 
Clinical outcomes were divided as follows: clini-
cal response implied amelioration of symptoms, while 
hematologic response included improvement of blood 
count.   
Results
Patient characteristics are shown in Table 1. There 
were 11 patients in total, six male and five female, 
median age 73, considered as high age. The leading 
underlying diagnosis was CLL, followed by NHL, 
and only one patient with myelofibrosis. The great 
majority of patients with hematologic malignancy 
were referred for radiotherapy at an advanced stage of 
the disease and only one patient had received no prior 
chemotherapy. Some details regarding previous che-
motherapy were not recorded in the chart, as follows: 
primary chemotherapy in NHL patients consisted of 
6-8 cycles of CHOP (cyclophosphamide, doxorubicin, 
vincristine, prednisolone) protocol, whereas primary 
chemotherapy in CLL patients predominantly in-
cluded chlorambucil, then CVP (cyclophosphamide, 
vincristine, prednisone) and protocols containing flu-
darabine and cyclophosphamide. The patients with 
myeloproliferative diseases received treatment with 
hydroxyurea, interferon alpha and corticosteroids for 
a short time.
All patients had pronounced extensive splenom-
egaly with apparent consequential clinical symptoms. 
These 11 patients treated with splenic irradiation 
received 16 courses of fractionated radiotherapy (Ta-
Table 1. Patient characteristics
Number of patients 11




Primary diagnosis, n (%)
CLL 4 (36.4)




Rai II 1 (25 %)
 Rai IV 3 (75%)
NHL 6 (100)
Stage IV 6 (100)
Previous treatment, n (%)
One line of chemotherapy 3 (27.3)
Two lines of chemotherapy 3 (27.3)
Three lines of chemotherapy 2 (18.2)
No chemotherapy 1 (9.1)
Unknown 2 (18.2)
Splenomegaly, n (%) 11 (100)
CLL = chronic lymphocytic leukemia; NHL = non-Hodgkin’s lym-
phoma
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ble 2). Nine patients had only one course of splenic 
irradiation, while two patients were re-irradiated (re-
ceived more than one course of splenic irradiation). 
More precisely, one patient had four courses of splenic 
irradiation within the period of two years, and an-
other one had two courses of splenic irradiation at 
two-year intervals. 
Regarding the cause of referral for splenic irradia-
tion, 6 of 16 treatment courses were started in order to 
relieve clinical symptoms (painful splenomegaly, ab-
dominal tumor, discomfort and pain accompanied by 
‘B’ symptoms, i.e. weight loss and night sweats). Only 
one course was initiated to treat severely impaired 
blood tests caused by hypersplenism. The remaining 
9 courses were carried out to treat both clinical symp-
toms and impaired blood tests. 
Both daily fractionation and thrice-weekly treat-
ment schedule were used. The median of fractions 
delivered per patient was 9. Furthermore, parallel op-
posed (AP-PA) or tangential fields were most com-
monly used.   
Total radiation dose delivered varied from 1 to 10 
Gy, median dose 7 Gy, while fraction size varied from 
0.5 to 1 Gy, median 1 Gy. In 4 courses, the treatment 
was initiated with fraction size of 0.5 Gy. Afterwards, 
during the treatment, the dose was increased to 1 Gy 
per fraction.
Regarding initial radiotherapy portal field area, 
the largest area was 13x18 cm (234 cm²). Out of 16 
courses, in 7 fields these areas were reduced due to 
spleen shrinkage. The results of radiotherapy applied 
are summarized in Table 3. 
Satisfactory clinical responses were recorded in 5 
of 6 courses initiated for symptom relief, whereas 1 
course led to no response (a patient with CLL). Out of 
9 courses initiated for both symptom relief and ame-
lioration of hematology findings, satisfactory clini-
cal response was achieved in 7 (four NHL and three 
CLL patients), and satisfactory hematologic response 
in 5 (three CLL and two NHL patients) cases. In this 
group, there were 2 and 4 non-responders, respec-
tively. The four non-response courses referred to three 
CLL patients and one NHL patient. One course was 
applied for abnormal hematology findings resulting 
from hypersplenism only, but induced no response 
(NHL patient). Only one patient had myelofibrosis 
Table 2. Radiotherapy details
Number of courses 16
Treatment frequency, n
    Daily fractionation 8
    Thrice-weekly fractionation 8
Number of fractions per patient
(median) 1-15 (9) 
Portal arrangement, n (%)
    AP-PA parallel opposed 7 (43.8)
    Direct anterior 2 (12.5)
    Tangential 7 (43.8)
Field area range, cm² (median) 60-234 (154)
Field area reduction, n (%) 7 (43.8)
Dose/fraction range, Gy (median) 0.5-1 (1)
Total dose range, Gy (median) 1-10 (7)
Table 3. Results
Radiotherapy courses applied for 
symptom relief, n (%) 6 (37.5)
    Satisfactory clinical response 5
    Not responded 1
Radiotherapy courses applied for 
symptom relief and abnormal 
hematology findings, n (%)
9 (56.3)
    Satisfactory clinical response 7
    Not responded 2
    Satisfactory hematologic response 5
    Not responded 4
Radiotherapy courses applied for 
abnormal hematology findings, n (%) 1 (6.3)
    Not responded 1






Temporary radiotherapy course interruption 2 (18.2)
Permanent radiotherapy course interruption 1 (9.1)
Erythrocyte transfusions 3 (27.3)
Platelet transfusions 2 (18.2)
Total patients 11 (100)
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and received one course of successful splenic irradia-
tion to treat excessive splenomegaly (extramedullary 
hematopoiesis) and consequential abdominal pain and 
discomfort.       
The majority of courses initiated for symptom 
control resulted in effective palliation (71%), while a 
significant number of courses started to treat hema-
tologic sequels of hypersplenism failed to produce de-
sired effects (50%). 
Toxicity
Toxicity data are presented in Table 4. Special pre-
caution was taken to monitor peripheral (complete) 
blood count and general status of the patient before 
each fraction of splenic irradiation. Sometimes, it is 
hard to distinguish features of advanced and deterio-
rating underlying malignant hematologic disease in 
patients referred for splenic irradiation and side effects 
of splenic irradiation itself. 
In our sample, the most common side effect was 
thrombocytopenia in four patients (two of them re-
quired platelet transfusion), followed by anemia re-
quiring red blood cell transfusion in three patients. 
Two patients had temporary radiotherapy course in-
terruption due to thrombocytopenia. Only one pa-
tient had pancytopenia. In four patients, hematologic 
toxicity seemed to be dose limiting. 
In one patient, the treatment was stopped at just 
1 Gy since there was no benefit and the patient was 
considered as a non-responder to splenic irradiation.     
Discussion
In our series of patients, splenic irradiation caused 
favorable palliative effect, which is comparable with 
other reports. There was no intent to cause complete 
response, rather to achieve hematologic response and 
relief of splenomegaly symptoms, although even com-
plete systemic remissions in all types of lymphopro-
liferative disorders have been observed after splenic 
irradiation9. 
Regarding the effects of splenic irradiation, they 
are mostly comparable with splenectomy, depending 
on the total dose of fractionated radiotherapy. Splenic 
irradiation is considered a local treatment, causing 
the kill of neoplastic cells homed in the spleen and 
a small proportion of circulating neoplastic cells oc-
curring in splenic vessels at the time of radiotherapy, 
but it can also induce systemic effects, probably due 
to the release of chemokines and other autocrine and 
paracrine regulatory molecules. Cell kill reduces the 
proportion of neoplastic cells in the spleen with con-
sequential decrease of tumor burden and ameliora-
tion of splenomegaly10. When considering therapeutic 
outcome of splenic irradiation, it should be noted that 
there are several types of response, e.g., regression of 
spleen, reduction of white blood count (WBC), nor-
malization of RBC and platelet counts, or complete 
remission. The majority of studies with splenic irra-
diation in CLL analyzed only few of these features, 
but all studies demonstrated the efficacy of splenic ir-
radiation through relief of symptoms associated with 
splenomegaly. Therefore, most cited responses were 
reduction of spleen size or relief of pain and abdomi-
nal discomfort. The response rate using these criteria 
in reported studies was 50%-90%3,4,6,7,9,11-13. Regard-
ing these clinical outcomes, our results are completely 
comparable. Another study outcome was reduction 
of increased WBC, recorded in a great proportion of 
CLL patients. In some studies, a considerable propor-
tion of patients (22%-38%) achieved complete hema-
tologic remission (remission in bone marrow, liver or 
lymph nodes), but this result could be achieved pre-
dominantly in the population of patients with pro-
lymphocytic and hairy cell leukemia, and in some 
cases of splenic lymphoma7,9. In our study, the above 
mentioned hematologic remission was not analyzed 
because the respective data were lacking. All our pa-
tients had a large tumor mass, most of them had bone 
marrow infiltration, therefore complete tumor regres-
sion was impossible. The results of splenic irradiation 
regarding treatment of anemia and thrombocytopenia 
are opposing, ranging from very good to modest7,12. 
A great variety of radiotherapy treatments have been 
reported. Most studies used single doses between 0.5 
and 1 Gy given daily or 1-3 times a week. Radiation 
therapy was applied until remission or significant re-
duction of spleen size. Total doses were 5-10 Gy and 
doses higher than 10 Gy provided no further spleen 
reduction3,14.  
The most effective dose and fractionation schedule 
in splenic irradiation is still unknown and is a matter 
of debate. Depending on the underlying disease, total 
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doses between 4 and 10 Gy, mostly in 1-Gy fractions, 
are used. Since there is no adequate evidence based 
data, different fractionation schemes have been suc-
cessfully used: daily, weekly, twice weekly and thrice 
weekly fractionation3,11,12. The total radiation dose de-
livered in our study varied from 1 to 10 Gy, with me-
dian dose of 7 Gy, while fraction size varied from 0.5 
to 1 Gy, with median of 1 Gy. The doses in our study 
were comparable with previous reports. There are sev-
eral mechanisms responsible for the effects of splenic 
irradiation. These are direct cell kill, immune modu-
lation, or ‘radiotherapeutic’ splenectomy10. In this set-
ting, splenic irradiation is the cause of hyposplenism 
and immunization with pneumococcus vaccine might 
be warranted. Our patients were pretreated with che-
motherapy and almost all were older than 65, which 
is appropriate for splenic irradiation. The majority of 
reports on CLL patients recommend the use of splen-
ic irradiation in elderly patients with predominant 
bone marrow lymphocytosis, in patients with previ-
ous extensive chemotherapy or radiotherapy, and in 
patients with poor marrow reserve. Splenic irradia-
tion is considered as a non-toxic treatment, therefore 
subsequent treatment is not compromised4. The main 
clinical indications for splenic irradiation are CLL, 
prolymphocytic leukemia, hairy cell leukemia, vari-
ous types of NHL, and myeloproliferative syndromes. 
Furthermore, splenic irradiation could synergistically 
improve therapeutic response in primary chemothera-
py resistant hairy cell leukemia15.
In our series, patients with NHL, all in stage IV, 
predominated. Since NHL is the most common he-
matologic malignancy infiltrating the spleen and de-
manding local and systemic therapy, these patients ac-
count for the largest share of all patients treated with 
splenic irradiation16. The second group were patients 
with CLL. Such a distribution is in accordance with 
other reported series of splenic irradiation.
One patient from our series had myelofibrosis. 
Another specific female patient with CLL had 
splenic irradiation in four courses (one primary treat-
ment and 3 re-irradiations for relapse). These treat-
ments were not associated with any major side ef-
fects. 
In some patients with excessive splenomegaly and 
lymphoproliferation predominantly restricted to the 
spleen, splenectomy could be the therapy of choice. 
Splenectomy is performed in patients with symptom-
atic splenomegaly refractory to chemotherapy, but 
it carries a substantial surgical risk17,18. Splenic irra-
diation is an effective alternative, with a considerably 
lower risk. All our patients had irradiation fields en-
compassing the whole spleen. Clinical target volume 
was defined by computerized tomography (CT), ab-
dominal ultrasonography and clinical examination. 
Enlarged spleen can fill the whole left hemiabdomen, 
with an increasing risk of spleen rupture. 
Enlarged spleen shrinks during the radiotherapy 
course, so it is necessary to adjust the target volume. It 
this case, palpation can be very easily performed and 
informative. In complicated cases, ultrasonography is 
needed. In our series, a meaningful proportion of pa-
tients had shrinkage of treatment field due to diminu-
tion of spleen during radiotherapy.   
The acute toxicity of splenic irradiation is low, es-
pecially when compared with cytotoxic chemothera-
py. In our patient series, toxicity was acceptable and 
they had completed their radiotherapy course mainly 
without serious side effects. The most common side 
effects included thrombocytopenia, anemia and pan-
cytopenia. Toxicity profile in our patients was in con-
cordance with other reports10,14,19. 
There were some limitations of our study. It was a 
retrospective study focused on treatment-related tox-
icity profile, feasibility and clinical setting rather than 
systemic response and survival because data regarding 
longer follow up and clinical outcome were lacking. It 
should be noted that splenic irradiation is a very rare 
and decreasingly required procedure, so it takes a long 
period to collect greater number of patients. In the 
future, we plan to acquire all necessary data to assess 
the real clinical value and effect of splenic irradiation 
in our setting and to compare it with other reports.  
Conclusion 
In properly selected patients, splenic irradiation 
can provide effective and low-toxic palliation. It can 
compensate for the shortcomings of systemic treat-
ment in various hematologic malignancies, especially 
in cases when splenectomy is neither possible nor nec-
essary. Although splenic irradiation is not so frequent 
treatment, in a multidisciplinary clinical setting in-
cluding hematologist and radiation oncologist it can 
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be considered as the treatment of choice, taking into 
account regular assessments, adequate fractionation, 
field reduction and monitoring of blood count.  
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Sažetak 
OZRAČIVANJE SLEZENE U BOLESNIKA SA ZLOĆUDNIM I DRUGIM HEMATOLOŠKIM 
BOLESTIMA – ISKUSTVA JEDNE BOLNIČKE USTANOVE
Ž. Soldić, J. Murgić, M. Jazvić, J. Radić, A. Bolanča, V. Stančić i Z. Kusić
Ozračivanje slezene je najstariji poznati način palijativnog liječenja bolesnika s različitim zloćudnim hematološkim 
bolestima. Ima za cilj umanjiti kliničke simptome splenomegalije, kao i posljedice hipersplenizma. Ozračivanje slezene ima 
značajan učinak uz nisku toksičnost, ali točna radioterapijska doza kao i način frakcioniranja nisu poznati. Između 1996. i 
2010. godine 11 bolesnika je liječeno u našoj ustanovi ovim postupkom. Ti bolesnici su primili ukupno 16 aplikacija frak-
cioniranog zračenja. Šest bolesnika je imalo ne-Hodgkinov limfom, četiri kroničnu limfatičnu leukemiju, a jedan bolesnik 
je imao mijelofibrozu. Medijan aplicirane tumorske doze bio je 7 Gy, a medijan aplicirane doze po frakciji 1 Gy. Korištena 
su nasuprotna paralelna te tangencijska radioterapijska polja. Zbog smanjenja kliničkog ciljnog volumena terapijsko polje 
je tijekom postupka radioterapije smanjeno u  44% radioterapijskih aplikacija. Od radioterapijskih postupaka započetih s 
ciljem kontrole simptoma 71% ih je rezultiralo uspješnom palijacijom, dok je od postupaka koji su započeti radi popravka 
hematoloških posljedica hipersplenizma njih 50% izazvalo željeni učinak. Najčešće nuspojave bile su trombocitopenija i 
anemija. Ozračivanje slezene omogućuje učinkovitu i nisko toksičnu palijaciju simptoma, ali je manje uspješno u liječenju 
hematoloških poremećaja uzrokovanih hipersplenizmom.       
Ključne riječi: Slezena, tumori – radioterapija; Palijativna skrb; Limfom, ne-Hodgkinov; Leukemija; Mijelofibroza

